PHAXIAM Therapeutics S.A.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of PHAXIAM Therapeutics S.A. generated cash of -$24,367,000, which is more than the previous year. Cash used in financing activities reached the amount of -$3,777,000 last year. Net change in cash is therefore -$28,315,000.
Cash Flow
| 2014 | -7.23M | -420.34K | 29.53M |
|---|---|---|---|
| 2015 | -14.57M | -284K | 23.52M |
| 2016 | -17.61M | -1.78M | 11.39M |
| 2017 | -24.70M | -1.79M | 177.54M |
| 2018 | -39.27M | -15.03M | -818K |
| 2019 | -43.31M | -19.83M | 40K |
| 2020 | -51.72M | -1.47M | 25.44M |
| 2021 | -56.77M | -345K | 44.71M |
| 2022 | -31.76M | 38.12M | -1.76M |
| 2023 | -24.36M | 171K | -3.77M |
PHXM Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 38.78M | 33.69M | 44.44M | 73.17M | 134.37M | 185.51M | 37.64M | 45.63M | 36.98M | 15.11M |
Operating activities | ||||||||||
Net income | -23.48M | -228K | -53.79M | -73.3M | -62.65M | -38.22M | -33.53M | -21.91M | -15.01M | -8.86M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.60M | 2.90M | 5.37M | 4.99M | 4.21M | 797K | 532K | 425K | 288K | 276.52K |
Stock-based compensation expense | 0 | 447K | 1.32M | 1.17M | 1.35M | 2.44M | 1.76M | 1.17M | 2.71M | 1.23M |
| Deferred income tax benefit | 0 | 447K | 1.32M | 1.17M | 1.35M | 2.44M | 1.76M | 1.17M | 2.71M | 1.23M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 218K | -63K | -8K | 33K | -7K | 47K | 142K | 206K | -319K | 0 |
Inventories | 0 | 9.28M | 0 | 358K | 1.03M | -1.21M | -31K | 21K | 32K | 0 |
Accounts payable | -1.21M | -9.22M | -6.47M | 6.91M | 5.99M | 8.57M | 3.24M | 1.16M | 1.58M | 0 |
Cash generated by operating activities | -24.36M | -31.76M | -56.77M | -51.72M | -43.31M | -39.27M | -24.70M | -17.61M | -14.57M | -7.23M |
Investing activities | ||||||||||
Purchases Of Investments | -4K | -5K | -192K | -421K | -119K | -812K | -102K | -40K | -15K | -103 |
Investments In Property Plant And Equipment | -217K | -85K | -298K | -1.14M | -20.13M | -14.22M | -1.68M | -1.75M | -269K | -421.43K |
Acquisitions Net | 32K | 37.63M | 0 | 2K | 16K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 171K | 38.12M | -345K | -1.47M | -19.83M | -15.03M | -1.79M | -1.78M | -284K | -420.34K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 34.63M | 118K | 47K | 0 | 177.57M | 10.03M | 23.60M | 31.38M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -94K | 0 | 0 |
Repayments of term debt | 0 | 0 | -1.70M | -1.67M | 0 | -818K | 0 | -563K | 0 | -281.34K |
Cash used in financing activities | -3.77M | -1.76M | 44.71M | 25.44M | 40K | -818K | 177.54M | 11.39M | 23.52M | 29.53M |
Net Change In Cash | -28.31M | 5.09M | -10.74M | -28.72M | -61.19M | -51.14M | 147.87M | -7.98M | 8.64M | 21.87M |
Cash at end of period | 10.47M | 38.78M | 33.69M | 44.44M | 73.17M | 134.37M | 185.52M | 37.64M | 45.63M | 36.98M |